skip to Main Content

Integrated Biotherapeutics, Inc. @ World Anti-Microbial Resistance Congress 2019

4 November 2019   INTEGRATED BIOTHERAPEUTICS TO PRESENT ON NOVEL VACCINES FOR MRSA AT WORLD ANTI-MICROBIAL CONGRESS 2019   Integrated Biotherapeutics, Inc. @ World Anti-Microbial Resistance Congress 2019   AN INDUSTRY EXPERTS CONFERENCE ON COMBATING ANTI-MICROBIAL RESISTANCE Maryland — 4 November 2019 – Integrated Biotherapeutics CEO Dr. M. Javad Aman will…

Read More

Production of Monoclonal Antibodies

Hybridoma Technology  History Monoclonal antibodies (mAbs) are monovalent (one epitope) antibodies derived from clones of a single parental immune cell. The original method for producing monoclonal antibodies is found in hybridoma technology. Prior to the production of monoclonal antibodies, polyclonal antibodies (multiple epitopes, multiple parental cells) were the standard for…

Read More

Alhydrogel Interference in Immunoassays

Troubleshooting immunoassays for adjuvanted vaccine products The safety record, affordability, and compatibility of aluminum to many antigens makes them a primary choice of adjuvant. Aluminum adjuvant compounds (such as aluminum hydroxide (Al(OH)3) and aluminum phosphate (AlPO4)) help maintain the physical and chemical characteristics of antigens and increase their repository effect…

Read More

Prophylaxis and immunotherapy of S. aureus/MRSA disease

Staphylococcus aureus (SA) is a Gram-positive bacterium that colonizes approximately one third of the human population1.  It causes a wide range of diseases from skin and soft tissue infections (SSTI) to life-threatening systemic disease such as bacteremia and pneumonia with high mortality rates2,3.  Currently, methicillin-resistant S. aureus (MRSA) is killing as many people…

Read More

Virus-like Particles: Tools for your infectious disease research

Virus-like particles (VLPs) are non-infectious nanoparticles that assemble from recombinantly expressed viral proteins but lack the viral genome required for replication and infection. Because they are non-infectious VLPs do not require the same level of biosafety containment as competent native viruses but retain the self-assembling and antigen presenting capabilities that…

Read More
Back To Top
×Close search
Search